TFA
HRTX icon

Tobias Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

Tobias Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,942
Closed -$69K – 148
2019
Q4 		$69K Buy
+2,942
New +$65.1K 0.04% 82

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tobias Financial Advisors's HRTX Position: Q1 2020 in Review

Tobias Financial Advisors sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 2,942 shares — an estimated $69K sold.

Tobias Financial Advisors first reported a position in HRTX in Q4 2019 and held it in 1 quarter. The position peaked at $69K in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

  • Tobias Financial Advisors reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Tobias Financial Advisors sold 2,942 Heron Therapeutics shares in Q1 2020, an estimated $69K.
  • Tobias Financial Advisors first reported a position in Heron Therapeutics in Q4 2019 and held it in 1 quarter.
  • Tobias Financial Advisors's Heron Therapeutics position peaked at $69K in Q4 2019.
  • 193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Tobias Financial Advisors's 13F filing for Q1 2020, filed 13 May 2020.